22 participants
A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2012-10-31
- Start Date:
- 2003-06-30
- Completion:
- 2005-10-31
Conditions
- Prostatic Neoplasms
- Metastases, Neoplasm
Interventions
- DRUG